| Revenue growth | 38% YoY consolidated growth in FY26. |
|---|---|
| Margins | Consolidated margins dipped due to R&D and bioequivalence study investments. |
| Demand visibility | Strong in chronic therapies (CNS, Urology) and anti-obesity (Semaglutide). |
| Management confidence | High; expanding into 40+ countries with niche portfolios. |
Growth
FY26 consolidated revenue at ₹854cr (up 38% YoY); PAT at ₹46cr (up 20% YoY).
Outlook
Targeting 30% B2C revenue contribution in FY27; guiding 25-30% growth in B2B segment.
Risks
Geopolitical issues delayed B2C launches; forex volatility in Venezuela/Bolivia; high working capital requirements in US distribution.
Earnings Call filed with NSE, NSE: REMUS. Summary written with AI assistance from the document.
Remus Pharmaceuticals Ltd: key numbers
- Share price
- ₹946.00
- Market cap
- ₹1,115 Cr
- Revenue (annual)
- ₹853.6 Cr
- Net profit (annual)
- ₹36.99 Cr
- P/E (TTM)
- 30.1×Sector 50.4×
- Promoter holding
- 70.95%
- FII holding
- 5.28%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Remus Pharmaceuticals Ltd
All →Remus Pharmaceuticals Dividend
Remus Pharmaceuticals Limited has fixed September 22, 2026, as the record date for determining shareholder entitlement to a final dividend of Rs. 0.50 per share.
Remus Pharmaceuticals Annual General Meeting
Remus Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the migration of its equity shares from the NSE Emerge platform to Main Board.
Remus Pharmaceuticals Merger & Restructuring
Remus Pharmaceuticals will incorporate a new subsidiary in the Dominican Republic for pharmaceutical distribution. The company will hold at least 51% of its share capital.
Remus Pharmaceuticals Management Change
Remus Pharmaceuticals Limited has appointed Mr. Ashutosh Naginbhai Valani as a Non-Executive Independent Director, effective September 2, 2026.
Remus Pharmaceuticals SME to Main Board Migration
Remus Pharmaceuticals' board approved the company's migration from the NSE SME Emerge platform to the Main Board. It also announced a new subsidiary in the Dominican Republic.
Remus Pharmaceuticals Earnings Call: Key Takeaways
Remus Pharmaceuticals delivered high double-digit revenue growth in H2FY26, driven by aggressive international B2C expansion in Latin America and new specialized therapy launches.